In this issue:

›  VivaGel® update

› New agrochemical partnership

› SPL7013 shows therapeutic potential in viral conjunctivitis

› Positive dendrimer-doxorubicin results

› Key patents obtained

› R&D tax refund received

› Momentum builds in nanomedicine

› Substantial holders increase their stake

Download: Shareholder Update: May 2013 ( pdf file, 1MB)

Starpharma is pleased to provide investors with the opportunity to listen to an audio interview with Chief Executive Officer Dr Jackie Fairley on Boardroom Radio (BRR).

Starpharma will today present to institutional fund managers at the Goldman Sachs Emerging Companies conference in Sydney.

 The invitation-only event involves 35 companies across all sectors.  Starpharma is one of three healthcare companies invited to attend - the other two are Blackmores and Sigma Pharmaceuticals.

Starpharma Holdings Ltd (ASX:SPL; OTCQX:SPHRY) today announced that the Company’s clinical-stage dendrimer SPL7013 has shown potent antiviral effect against adenovirus, the agent responsible for the majority of viral conjunctivitis cases.

Starpharma today released its Appendix 4C - Quarterly Cashflow Report for the period ended 31 March 2013.

Starpharma today announced it has been granted three new patents by the United States Patent and Trademark Office (USPTO) which strengthen and expand the Company’s patent estate for its drug delivery platform.

In addition, China’s patent office has also informed the Company that it has allowed a similarly broad, drug delivery-related patent.

ABC News’ The Business Presenter Ticky Fullerton interviewed Starpharma CEO Dr Jackie Fairley on Thursday 4^th April 2013. Ticky discussed the positive results of Starpharma’s Phase 2 prevention of recurrence BV trials.

 Read the Transcrip (external link)

AAP business reporter Trevor Chappell investigates Starpharma’s positive results for its Phase II trial of VivaGel to prevent recurring bacterial vaginosis (R-BV). The results demonstrated a reduced overall risk of R-BV.

"The commercial opportunity for recurrent BV is very attractive, with an estimated market of more than $1 billion," said Starpharma CEO Dr Jackie Fairley.

 Go to the article (external link)

Starpharma  today announced the positive results of its exploratory Phase 2 study of VivaGel^® for the prevention of recurrent bacterial vaginosis (R-BV).  The results showed a reduced overall risk of R-BV during the study in patients using 1% VivaGel^® and time to first recurrence was delayed compared with placebo.

Herald Sun’s In The Black columnist, John Beveridge reported on Starpharma and its collaboration with Nufarm and Israel’s Makhreshim Agan, trading in Australia as Farmoz. These collaborations are a vote of confidence to the versatility of Starpharma’s dendrimer technology. "Dendrimers, nanoparticles that can greatly improve water solubility, are ideally suited to improving farming chemicals. In the case of weedkillers such as glyphosate, the addition of the right sort of dendrimer at the right levels can make the weedkiller much faster and more effective to use and able to be applied close to rain. For other agricultural chemicals the advantage is even greater, allowing the removal of dangerous solvents used to make theactive ingredient soluble and allowing the production of concentrates that are much easier to transport and can be mixed with water on site."